IDAYANTI, Nur and Sutiningsih, Dwi and Hadi, Mochammad (2022) KAJIAN RESPON IMUN HUMORAL IgG ANTI S-RBD SARSCoV- 2 SETELAH VAKSINASI CORONAVAC COVID-19 (Studi di Kantor Kesehatan Pelabuhan Kelas II Semarang, Jawa Tengah). Masters thesis, School of Postgraduate Studies.

	Text COVER.pdf Download (1MB)
	Text BAB I.pdf Download (366kB)
	Text BAB II.pdf Download (782kB)
	Text BAB III.pdf Restricted to Repository staff only Download (200kB)
	Text BAB IV.pdf Restricted to Repository staff only Download (369kB)
	Text BAB V.pdf Restricted to Repository staff only Download (345kB)
	Text BAB VI.pdf Restricted to Repository staff only Download (489kB)
	Text BAB VII.pdf Download (171kB)
	Text Daftar Pustaka.pdf Download (324kB)
	Text Lampiran.pdf Restricted to Repository staff only Download (2MB)

Abstract

Latar Belakang: Vaksinasi menjadi salah satu upaya dalam pengendalian Covid-19. Kajian respon imun humoral post vaksinasi masih terbatas di Indonesia.
Tujuan: Penelitian ini bertujuan menganalisis respon imun humoral melalui IgGanti S-RBD SARS-CoV-2 setelah vaksinasi Coronavac Covid-19.
Metode: Penelitian dengan rancangan cross sectional ini melibatkan 50 tenaga kesehatan dari total populasi di Kantor Induk KKP Kelas II Semarang yang memenuhi kriteria inklusi dan ekslusi yang telah diberikan vaksinasi inactive (Coronavac). Pengukuran IgG anti S-RBD SARS-CoV-2 menggunakan metode Chemmiluminescent Immuno Assays (CLIA) dan pertanyaan quesioner menggunakan google form. Analisis data terdiri atas analisis univariat dan bivariat.
Hasil Penelitian: Rerata kadar antibodi IgG anti S-RBD SARS-CoV-2 paling tinggi (1000 AU/ml) pada subjek setelah vaksinasi kemudian ada paparan infeksi Covid-19, diikuti subjek vaksinasi dengan ada paparan infeksi alami sebelumnya (147,6 AU/ml), sedangkan subjek tervaksinasi dengan tidak ada paparan infeksi rata-rata 14,36 AU/ml pada waktu setelah vaksinasi 23-188 hari (rata-rata 149 hari). Setelah pemberian vaksin Coronavac sebesar 32% subjek mengalami infeksi SARS-CoV-2 pada 94-155 hari (rata-rata 131 hari) dengan rerata kadar IgG anti SRBD 1000 AU/ml. Hal ini dapat diindikasikan bahwa pemberian vaksin inactive menginduksi sel memori untuk respon imun sekunder. Pada subjek dengan penyakit penyerta respon imun lebih rendah dibanding dengan tidak ada penyakit penyerta. Selain itu menunjukan sebanyak 41(82%) menunjukkan reaktif atau seropositive IgG anti S-RBD SARS-CoV-2. Temuan kami juga menunjukan bahwa subjek yang terpapar infeksi setelah pemberian vaksinasi inactive (Coronavac) 100% bergejala ringan tidak membutuhkan perawatan Rumah Sakit. Ada perbedaan signifikan kadar IgG anti S-RBD SARS-CoV-2 setelah pemberian vaksinasi pada variabel status paparan, penyakit penyerta dan waktu setelah infeksi. Tidak ada perbedaan signifikan kadar IgG anti S-RBD SARS-CoV-2 pada variabel umur, jenis kelamin, waktu setelah vaksinasi, indeks massa tubuh, dan tingkat stres.
Kesimpulan: Status paparan, penyakit penyerta dan waktu setelah infeksi sangat mempengaruhi kadar IgG anti S-RBD SARS-CoV-2.
Kata Kunci: Vaksin inactive, Coronavac, IgG anti S-RBD, SARS-CoV-2, Covid-19

Background: Vaccination is an attempt of controlling Covid-19. Studies on postvaccination humoral immune response are still limited in Indonesia.
Objective: This research aims to analyze the humoral immune response through anti-S-RBD SARS-CoV-2 IgG after Coronavac vaccination.
Method: This research with cross sectional design involved 50 healthcare workers that have received Coronavac vaccination in Health Quarantine of Class II Semarang. The measurement of anti S-RBD SARS-CoV-2 IgG was conducted using Chemmiluminescent Immuno Assays (CLIA) method and questionnaire was distributed using google form. Data analysis consisted of univariate and bivariate analysis.
Result: The subject post vaccination and later infected with Covid-19 has the highest mean anti S-RBD SARS-CoV-2 score (1000 AU/ml), followed by the subject post vaccination with previous infection history (147.6 AU/ml), and the subject post vaccination without infection history (14.36 AU/ml) 23-188 days
(mean 149 days) after vaccination. After administration of the Coronavac, 32% of subjects experienced SARS-CoV-2 infection at 94–155 days (mean 131 days) with an average level of anti-S-RBD IgG 1000 AU/ml. This may indicate that the administration of Coronavac induces memory cells for a secondary immune
response. In subjects with comorbidities, the immune response is lower than in those without comorbidities. In addition, it showed that in the range after 23–188 days of vaccination, 41 (82%) showed reactive or seropositive IgG anti-S-RBD SARS-CoV-2. Our findings also show that subjects exposed to infection after the administration of 100% Coronavac vaccination had mild symptoms and unhospitalization On the variables of exposure status, co-morbidities, and time after infection, there was a significant difference in IgG anti-S-RBD SARS-CoV-2 levels after vaccination. There was no significant difference in the levels of IgG anti-SRBD SARS-CoV-2 on the variables of age, sex, time after vaccination, body mass index, and stress levels.
Conclusion: Exposure status, comorbidities, and time after infection greatly affect the levels of IgG anti-S-RBD SARS-CoV-2.
Keywords: Inactive vaccine, Coronavac, anti S-RBD IgG, SARS-CoV-2, Covid-19

Actions (login required)

View Item